Francois Salmon

Teledyne LeCroy, Inc. provides oscilloscopes and protocol analyzers. Its products include oscilloscopes, protocol analysers, waveform generators, logic analyzers, optical modulation analyzer, and signal integrity studio. The company was founded by Walter LeCroy in 1964 and is headquartered in Chestnut Ridge, NY.

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland.

Acrostak Corp. is a Swiss company that specializes in medical devices for interventional cardiology. The private company is based in Geneva, Switzerland. The company's focus is on chronic total occlusion and they offer PTCA balloons and percutaneous coronary intervention devices.

Value Italy SGR SpA (Value Italy) is an independent private equity firm founded in 2001. The firm is headquartered in Florence, Italy.

Genevest Consulting Group SA is an independent Swiss venture capital firm which was founded in 1983 to provide advisory services to institutional investors and high-net worth individuals. Based in Geneva, Genevest operates in close cooperation with Endeavour Vision SA.

Permobil AB engages in the manufacture and sale of electric wheelchairs and accessories. It focuses on pediatrics, outdoor, and indoor use for mobility and rehabilitation. The company was founded by Per Uddén in 1963 and is headquartered in Timra, Sweden.

Innogest SGR SpA (Innogest) is a private equity firm founded in 2005 by Claudio Giuliano and Marco Pinciroli. The firm is headquartered in Milan, Italy.

EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy.

Molnlycke Health Care U.S. LLC manufactures surgical and wound care products. It offers drapes, procedure trays, surgical powder free gloves, and skin antiseptics. The firm's brands include Biogel, Mepilex, Mepitel, Mepore, Tubigrip, and Xelma. The company is headquartered in Norcross, GA

Mölnlycke Health Care, Inc. provides single use surgical and wound care products and services to the health care sector. It also provides logistics, education support, cost control, and consulting services. The company was founded in 1997 and is headquartered in Oakville, Canada.

Péters Surgical SASU manufactures dentistry and medical equipment. The company was founded in 1926 and is headquartered in Bobigny, France.

Molnlycke Health Care SAS wholesales pharmaceutical products. The company was founded on October 24, 1991 and is headquartered in Wasquehal, France.

Mölnlycke Health Care Ltd. engages in the sale and distribution of single-use products for surgical interventions and wound care to the professional health care sector. The company was incorporated on January 12, 1998 and is headquartered in Oldham, the United Kingdom.

Mölnlycke Health Care AS designs and provides medical solutions. The firm supplies disposable products for surgery and wound treatment to customers, healthcare professionals, and patients. Its products include wound care, skin and scar treatment, antiseptic products, compression equipment, and dental products. The company was founded in 1997 and is headquartered in Oslo, Norway.

STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain.

Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.

Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.

Avitide, Inc. develops affinity purification solutions. Its technology enables development of chromatography resins via chemical synthesis which are not based on costly recombinant proteins. The company was founded by Errik B. Anderson, Warren Kett, Tillman U. Gerngross, Kevin Isett and Jonathan Sheller in 2012 and is headquartered in Lebanon, NH.

SoniVie Ltd. engages in the development of a system for the treatment of pulmonary hypertension. Its products include Therapeutic Intra-Vascular Ultrasound (TIVUS) system, an intravascular, catheter-based technology that can cause denervation of nerves surrounding blood vessels and other structures like the bronchus. The company was founded by Moshe Arkin in 2014 and is headquartered in Rosh Haayin, Israel.

Cardiovascular Lab SpA provides health care services. The firm is a bridge between great ideas from physicians and international capital. The company was founded in 2016 and is headquartered in Turin, Italy.

Part of Sienna Biopharmaceuticals, Inc., Creabilis UK Ltd. engages in research and development of biological products. The company is based in Canterbury, UK.

Bio4Dreams SpA (Bio4dreams) is a venture capital firm founded in 2017 by Pietro Conti, Laura Iris Ferro, Elisabetta Borello and Cusi Daniele. The firm is headquartered in Milan, Italy.

Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY.

Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland.

EBAMed SA develops solutions for non-invasive and automated treatment of heart arrhythmias. The company was founded by Adriano Garonna and Leo Giovanni and is headquartered in Geneva, Switzerland.

EFI Lake Geneva Ventures ICAV (EFI Lake Geneva Ventures) is a venture capital firm founded in 2020 by Toby Main and Sandy Koifman. The firm is headquartered in Geneva, Switzerland.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.

NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.

Medyria AG develops technologies for endovascular catheter navigation and sensing. Its products include trackcath, flowcath and OEM flow sensor. The firm's technology is a sensor-based system combined with a novel approach for processing flow data and tracking catheters. The targeted medical domains comprise vascular, valve, and heart procedures. The company's products increase accuracy reducing complications and risks, fostering the conversion from open surgery to minimally invasive approach. Medyria was founded by Mauro Massimo Sette in 2012 and is headquartered in Winterthur, Switzerland.